Clinical trials: Non-Specific Effects of Vaccines
Infant Morbidity, Infant Mortality
BCG Revaccination With the Third Dose of Diphtheria-tetanus-pertussis Vaccine and Infant Mortality in Africa
Studies in low-income countries show that vaccines can have important non-specific effects on other infections. Live BCG vaccine can train the immune system and reduce susceptibility to unrelated infections.
- Conditions
- Infant Morbidity, Infant Mortality, Non-Specific Effects of Vaccines, BCG
- Trial name
- BCG2-DTP3 (NCT07005726)
- Testing
- BCG Vaccine
- Where
- Guinea-Bissau
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
COVID-19, Non-specific Effects of Vaccines
Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic
Background: The COVID-19 pandemic challenges the available hospital capacity, and this will be augmented by absenteeism of healthcare workers (HCW).
- Conditions
- COVID-19, Non-specific Effects of Vaccines, Morbidity, Absenteeism
- Trial name
- NCT04373291
- Testing
- BCG-Denmark, Saline
- Where
- Denmark
- Volunteers
- 1,293 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
Early Neonatal Mortality
A Randomized Trial of Providing BCG Vaccination Immediately
Recent studies show that BCG vaccination reduces neonatal mortality by more than 40%. This effect cannot be explained by prevention of tuberculosis, which is very rare among infants.
- Trial name
- NCT01989026
- Testing
- BCG
- Where
- Guinea-Bissau
- Volunteers
- 3,361 people
- Sponsor
- Bandim Health Project
Measles
Non-Specific Effects of Standard Titre Measles Vaccination
The general objectives of the proposed research work are: A1) to reduce childhood mortality in developing countries through better control of measles infection by finding the best immunization strategy, and A2) to investigate the…
- Trial name
- NCT00168662
- Testing
- Measles and inactivated polio vaccine
- Where
- Guinea-Bissau
- Volunteers
- 7,800 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
COVID-19, Vaccine Reaction
Investigating COVID-19 Vaccine Immunity in Children in the Melbourne Infant Study of BCG for Allergy and Infection Reduction
The COSI BAIR trial will involve approximately 60 children, aged 5 to 8 years old, comprising a subset of participants from the Melbourne Infant Study BCG for Allergy and Infection Reduction (MIS BAIR) randomised controlled…
- Conditions
- COVID-19, Vaccine Reaction, Immunization; Infection
- Trial name
- COSI BAIR (NCT05168709)
- Testing
- Tozinameran
- Where
- Australia
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Child Mortality, Child Morbidity
A Second Dose of Measles Vaccine (MV) in the Second Year of Life
This study evaluates the non-specific effects on child mortality and morbidity of a second dose of measles in the second year of life.
- Trial name
- NCT02943681
- Testing
- Measles vaccine
- Where
- Guinea-Bissau
- Volunteers
- 3,812 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
Influenza-like Illness, Upper Respiratory Disease
Non-specific Effects of Rabies Vaccine
Vaccines work by stimulating the body to produce a high-quality, rapid and specific immune response upon exposure to infection by a particular disease-causing microorganism - the microorganism targeted by the vaccine.
- Conditions
- Influenza-like Illness, Upper Respiratory Disease, Diarrhea, Fever
- Trial name
- NCT03656198
- Testing
- Rabivax-S, Sterile Water Injection
- Where
- Saint Kitts and Nevis
- Volunteers
- 546 people, healthy volunteers welcome
- Sponsor
- Ross University School of Veterinary Medicine
Measles Infection
Additional Measles Vaccine at 4 Months of Age
Overall objective: To conduct a randomised controlled trial (RCT) to examine whether an early two-dose measles vaccination (MV) strategy at 4 and 9 months will reduce child mortality compared with the WHO strategy of one dose of…
- Trial name
- NCT01486355
- Testing
- Measles vaccine
- Where
- Guinea-Bissau
- Sponsor
- Bandim Health Project
Cancer
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
RATIONALE: Vaccines may help the body build an effective immune response to kill cytomegalovirus infections. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients who have…
- Trial name
- NCT00509691
- Testing
- cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Louisville
Covid19, Morbidity
BCG to Reduce Absenteeism Among Health Care Workers During the COVID-19 Pandemic
The COVID-19 pandemic challenges available hospital capacity. Strategies to protect health care workers (HCW) are desperately needed.
- Conditions
- Covid19, Morbidity, Absenteeism
- Trial name
- EDCTP (NCT04641858)
- Testing
- BCG-Denmark, Saline
- Where
- 2 sites in Guinea-Bissau, Mozambique
- Volunteers
- 668 people, healthy volunteers welcome
- Sponsor
- University of Southern Denmark
Non-target Heterologous Effects of Vaccines, Vaccine Interactions
The Interaction Between Measles and DTP Vaccination
The purpose of this study is to investigate for the broad immunological effects of administering measles vaccine (MV) and diphtheria-tetanus-whole cell pertussis vaccine (DTP) to 9 month old Gambian infants, either alone or…
- Trial name
- NCT02710045
- Testing
- Measles Vaccine at 9 months of age, DTP Vaccine at 9 months of age, Measles Vaccine at 18 months of age
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- Medical Research Council Unit, The Gambia
Measles Vaccine
Trial of Additional Measles Vaccine to Reduce Child Mortality
Background: All observational studies and a few randomised controlled trials (RCT) suggest that early measles vaccine (MV), in particular an early two-dose strategy, has a much better effect on overall mortality than later MV.
- Trial name
- NCT01644721
- Testing
- Early measles vaccine
- Where
- Guinea-Bissau
- Volunteers
- 3,750 people
- Sponsor
- Bandim Health Project
BCG Vaccination
Role of BCG as Booster Vaccination
The BCG (bacillus Calmette-Guerin) vaccine is used for the protection against tuberculosis. Apart from it's protective effect against tuberculosis BCG vaccine has been shown to have non-specific effects on the innate immune…
- Trial name
- NCT02175420
- Testing
- BCG, TFV
- Where
- Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Innate Immunity, Bacille Calmette-Guérin
Testing if BCG (Bacille Calmette-Guérin) Vaccination Can Induce Innate Immune Training in Adult People Above 50 Years of Age in Guinea-Bissau
The propose is to test innate immune training in a pilot study of 40 adults >50 years of age people in Guinea-Bissau. The hypothesis is that BCG vaccination will be associated with increased innate immune training measured as…
- Trial name
- NCT02953327
- Testing
- Bacille Calmette-Guerin, BCG solvent
- Where
- Guinea-Bissau
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
Measles
Early Two-dose Measles Vaccination Trial
The specific aims are to examine in Guinea-Bissau: whether the standard titre Schwarz (SW) or standard-titre Edmonston-Zagreb (EZ) measles vaccine will be the best vaccine strain for use in a routine one-dose measles vaccination…
- Trial name
- NCT00168558
- Testing
- Measles vaccine
- Where
- Guinea-Bissau
- Volunteers
- 5,879 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
Vaccine Preventable Disease, Measles
Measles and BCG Vaccines for Mother and Child
In Africa, the mortality from infectious diseases remains high. The investigators have discovered that live vaccines such as the BCG vaccine against tuberculosis and the measles vaccine can strengthen resistance to other…
- Conditions
- Vaccine Preventable Disease, Measles, Mother-Infant Interaction, BCG Vaccination Reaction
- Trial name
- MATVAC (NCT04899765)
- Testing
- BCG vaccine, Measles vaccine
- Where
- Guinea-Bissau
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project